Peg L‑Asparaginase

Peg L-Asparaginase, commonly referring to pegylated L-asparaginase and, in established formulations, pegaspargase, is an enzyme-based anticancer medicine used in combination chemotherapy for acute lymphoblastic leukaemia (ALL). It belongs to the asparaginase class of antineoplastic agents. The medicine contains the enzyme L-asparaginase attached to polyethylene glycol, a modification that prolongs its activity in the body compared with some non-pegylated formulations. Its principal mechanism involves breaking down the amino acid asparagine in the bloodstream. Many lymphoblasts, the immature white blood cells involved in ALL, have limited capacity to produce sufficient asparagine themselves and depend on its external supply for protein synthesis and survival. Depleting circulating asparagine can therefore inhibit the growth and survival of susceptible leukaemia cells. Peg L-Asparaginase is administered by a healthcare professional, usually through an intravenous infusion or, for appropriate formulations and protocols, an intramuscular injection. It is not ordinarily used as a standalone treatment; it forms part of a multi-agent chemotherapy regimen selected according to the patient's age, disease characteristics, treatment phase and clinical condition. Its prolonged activity can reduce the frequency of administration compared with some native asparaginase preparations. Careful monitoring is essential because treatment can cause hypersensitivity, pancreatic inflammation, liver toxicity, metabolic disturbances and abnormalities in blood clotting.

L-asparaginase became an important component of ALL treatment after research demonstrated that depletion of circulating asparagine could suppress susceptible leukaemia cells. Pegylation was developed to extend enzyme persistence and reduce the frequency of administration. Pegaspargase received its initial United States Food and Drug Administration (FDA) approval on 1 February 1994 for use in combination chemotherapy in patients with ALL who were hypersensitive to native forms of L-asparaginase. The FDA subsequently approved the related product calaspargase pegol in December 2018 for use in a multi-agent chemotherapy regimen in patients with ALL aged one month to 21 years. Calaspargase pegol is a distinct pegylated asparaginase formulation and should not be treated as interchangeable with pegaspargase without specific clinical and regulatory guidance. In the European Union, Oncaspar, containing pegaspargase, received marketing authorisation on 14 January 2016 for use as a component of combination therapy for ALL in paediatric patients and adults. Its development and assessment included clinical studies evaluating efficacy, enzyme activity, hypersensitivity and safety in leukaemia treatment protocols. Approval conditions, formulations and authorised indications vary across countries. In India, the current status of a particular Peg L-Asparaginase product must be checked against the Central Drugs Standard Control Organisation (CDSCO) requirements and the product's locally authorised prescribing information. The clinical evidence base includes studies of pegaspargase in combination chemotherapy, including protocols for newly diagnosed and relapsed ALL.

Peg L-Asparaginase is used as a component of multi-agent chemotherapy for acute lymphoblastic leukaemia, a malignancy involving immature lymphoid cells. The specific authorised population depends on the formulation, country and treatment protocol. Depending on the applicable product approval, it may be used in children, adolescents and adults as part of induction, consolidation, intensification or other phases of ALL treatment. The medicine is combined with other anticancer agents rather than generally administered as monotherapy. Treatment decisions depend on the patient's age, ALL subtype, risk classification, previous treatment, response to therapy, allergy history and ability to tolerate asparaginase. Some formulations or treatment protocols may be considered when patients have developed hypersensitivity to a different asparaginase preparation, but cross-reactivity, enzyme activity and product-specific eligibility must be assessed by the treating specialist. Peg L-Asparaginase is not a general treatment for all forms of leukaemia and should not be assumed to be indicated for acute myeloid leukaemia or other cancers. The precise indication, dose and schedule must follow the authorised product information and the specialist's chosen ALL protocol.

Peg L-Asparaginase is administered by intravenous infusion or intramuscular injection, depending on the specific product, approved route and chemotherapy protocol. Dosing is generally calculated according to body surface area and expressed in international units per square metre. A dose of 2,500 IU/m² at intervals of approximately 14 days is used in certain pegaspargase regimens, but this is not a universal schedule; age-specific recommendations, treatment protocols, formulation-specific instructions and enzyme activity monitoring may require a different dose or interval. Treatment is scheduled according to the overall chemotherapy plan rather than a single standard duration. Administration should take place under the supervision of a qualified oncology team with facilities and medicines available to manage anaphylaxis and other acute reactions. Patients require assessment before dosing, including liver function, pancreatic symptoms, glucose levels, coagulation status and relevant blood counts. Some protocols also use serum asparaginase activity testing to evaluate enzyme exposure, particularly when hypersensitivity, silent inactivation or inadequate activity is suspected. Treatment may be delayed, modified or discontinued following severe toxicity. Patients should never calculate, alter or repeat a dose themselves.

Common adverse effects of Peg L-Asparaginase include abnormal liver function tests, elevated bilirubin, nausea, vomiting, reduced appetite, abdominal discomfort, fatigue, increased blood glucose and changes in blood clotting parameters. Patients may also experience reduced blood cell counts, fever, headache, swelling or infusion-related reactions, although the frequency varies according to the chemotherapy regimen and the specific formulation. Changes in liver function can range from laboratory abnormalities to clinically significant hepatic injury. Hyperglycaemia may be more pronounced when the medicine is administered alongside corticosteroids or other medicines that affect glucose metabolism. Because ALL treatment generally involves several anticancer agents, it can be difficult to attribute every symptom to one medicine without clinical assessment. Many adverse effects can be managed through laboratory monitoring, supportive care, treatment delays or dose modification when appropriate. Patients and caregivers should promptly report new abdominal pain, persistent vomiting, yellowing of the skin or eyes, unusual bruising, bleeding, severe headache, leg swelling, breathing difficulties or symptoms of infection. Supportive medicines and dietary changes should be discussed with the treating team.

Important serious risks include severe hypersensitivity and anaphylaxis, pancreatitis, serious liver injury, thrombosis, haemorrhage and significant metabolic disturbances. Pancreatitis can present with persistent or severe abdominal pain, sometimes accompanied by vomiting, and may require immediate treatment interruption and specialist assessment. Asparaginase-associated reductions in clotting proteins can increase the risk of both bleeding and thrombosis, including potentially serious blood clots in cerebral or other vessels. Severe hepatic toxicity, including substantial increases in liver enzymes or bilirubin and, in some cases, hepatic dysfunction, may occur. Hyperglycaemia and, rarely, serious metabolic complications may require urgent treatment. Serious hypersensitivity reactions can occur during administration or subsequent exposure; appropriate monitoring and emergency treatment facilities are therefore essential. Previous pancreatitis, severe thrombosis or bleeding associated with asparaginase, serious hypersensitivity and severe hepatic disease may constitute contraindications or reasons to avoid further treatment, depending on the exact product information. Patients with suspected severe toxicity require immediate clinical evaluation. Treatment may need to be withheld or permanently discontinued according to the nature and severity of the reaction, recovery, enzyme activity results and the applicable prescribing information.

Before treatment, clinicians should review previous exposure to asparaginase products, allergy history, liver function, pancreatic history, glucose control, coagulation parameters, blood counts and relevant medical conditions. Baseline and ongoing assessment should be guided by the chemotherapy protocol and the patient's risk factors. Particular caution is required in patients with diabetes, liver impairment, previous pancreatitis, clotting disorders, active infection or a history of serious thromboembolic events. Concomitant corticosteroids may increase the risk of hyperglycaemia, while other chemotherapy agents can contribute to liver toxicity, bone marrow suppression or infection. Asparaginase can alter the production of circulating proteins, including clotting factors, and may affect the safety or activity of anticoagulant treatment; medication review and coagulation monitoring are therefore important. It may also affect the tolerability or effectiveness of other chemotherapy medicines, so the sequence and timing of treatment should follow an established protocol. Pregnancy and breastfeeding require specialist assessment because anticancer treatment may pose significant risks to the developing child. Live vaccines may be inappropriate during intensive immunosuppressive chemotherapy, and vaccination timing should be reviewed by the oncology team. Patients should disclose all prescription medicines, over-the-counter products and supplements. The exact product information must be checked because precautions and interaction guidance may differ between pegylated asparaginase formulations.

Prescribers and pharmacists should verify the exact asparaginase formulation, product strength, authorised route and chemotherapy protocol before dispensing or administration. Pegaspargase and calaspargase pegol are distinct products and should not be substituted on a unit-for-unit basis without an approved protocol and specialist guidance. Confirm the prescribed dose calculation, body surface area, treatment phase and planned interval. Review baseline liver function, glucose, coagulation parameters, pancreatic history and previous hypersensitivity reactions. Administration should occur in a setting equipped to recognise and treat anaphylaxis, with appropriate observation according to the product information. During treatment, monitor for abdominal pain, liver injury, hyperglycaemia, thrombosis, bleeding and infusion reactions. Consider serum asparaginase activity monitoring where recommended by the treatment protocol or when inadequate enzyme exposure is suspected. Review concomitant corticosteroids, anticoagulants and other hepatotoxic or myelosuppressive medicines. Counsel patients and caregivers to report symptoms promptly and not to miss scheduled laboratory assessments. Maintain clear records of the formulation, dose, administration date, adverse reactions and any treatment interruption. Coordination among haematologists, oncology pharmacists, nurses, laboratory services and supportive-care teams is essential for safe delivery of multi-agent ALL therapy.